Slide 1: Corporate Overview
August 7, 2025 Corporate Overview
Slide 2: Notice Regarding Forward-Looking Statements
Notice Regarding Forward-Looking Statements This presentation and the accompanying oral presentation (the “Presentation”) include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections
Slide 3: Inogen is a Global Leader in Respiratory Therapy
Inogen is a Global Leader in Respiratory Therapy We offer innovative solutions for patients with chronic respiratory conditions. Improving Lives Through Respiratory Care ©©2025 2023Inogen, Inc. Inogen, Inc.AllAllRights RightsReserved Reserved. 3
Slide 4: The Problem: Chronic Obstructive Pulmonary Disease (COPD)
The Problem: Chronic Obstructive Pulmonary Disease (COPD) COPD impacts over 450 million lives globally and will affect 600 million by 2050 1 COPD was the 6th leading cause of death in the U.S. in 2020 2 ~$50B cost to healthcare systems annually in the U.S. 3 15.4M physician visits 4, over 1M E.R. vi
Slide 5: Our Solution: Portable, Long-Term Oxygen Therapy
Our Solution: Portable, Long-Term Oxygen Therapy Long-term oxygen therapy has been shown to help COPD patients who have severely low blood oxygen 1 Portable oxygen concentrators are alternatives to traditional portable systems such as compressed oxygen cylinders and are preferred by patients based o
Slide 6: Our Multi-Channel Business Model
Our Multi-Channel Business Model Direct-to-Consumer Marketing Patient Patient Call Center Website Rental/Prescriber Physician’s Office Patient Business-to-Business DME/HME Patient Distributor ©©2025 2023Inogen, Inc. Inogen, Inc.AllAllRights RightsReserved Reserved. 6
Slide 7: Strategic Priorities for Value Creation
Strategic Priorities for Value Creation Drive Top-Line Growth Advance Path to Profitability Expand Innovation Pipeline Increasing synergies and efficiencies Worked through the majority of Received SIMEOX 200 U.S. Regulatory across sales channels COVID-related premium priced Clearance Returni
Slide 8: Opportunity to Drive Growth and Profitability Over Time
Opportunity to Drive Growth and Profitability Over Time Our Differentiators Entering underserved airway clearance market with clinically differentiated offering Best in class products with trusted brand Commercial strategy with multiple call-points to drive growth and profitability Expansive product
Slide 9: Advantages of Portable Oxygen Concentrators
Advantages of Portable Oxygen Concentrators Clinical Evidence Supports Portable Oxygen Concentrators 1,2,3 Patients using a POC, alone or in combination, had a 13% reduced mortality risk than patients using a stationary concentrator 1 The estimated mortality risk for patients in the POC group 2
Slide 10: Expansive Market Opportunity for POCs in the U.S.
Expansive Market Opportunity for POCs in the U.S. Market Opportunities 1 Key Market Insight from Market Research 1, 2 4.1M Patients on Oxygen Therapy in 2024 SOC + POC Based on internal insights and independent research 3, the portable oxygen concentrator device SOC + Portable Tank 23% market is e
Slide 11: Our Innovation - Past and Future
Our Innovation - Past and Future Building on our deep knowledge Sharpen focus on clinically relevant Differentiate beyond devices, to and expertise in the oxygen innovations with the help of Inogen’s allow patients and clinicians better therapy market Scientific Advisory Board manage respiratory dis
Slide 12: Inogen Connect: Differentiating at the DME Through Digital Solutions
Inogen Connect: Differentiating at the DME Through Digital Solutions Increasing Accessibility for Patients While Saving DMEs Time and Money Receive important software updates and Help our business partners manage their maintenance reminders device fleet for patients using a compatible Inogen POC Che
Slide 13: Launched in Q1 2025: Inogen Web Patient Portal
Launched in Q1 2025: Inogen Web Patient Portal to Drive Inogen Resupply and Operational Efficiency Targeting an Improved Patient Experience While Streamlining Business Operations Order accessories and / or supplies Track orders Enhance engagement by allowing Submit a support request patients to inde
Slide 14: Launched in Q2 2025: Voxi 5, Continuous Flow. Continuous Care
Launched in Q2 2025: Voxi 5 , Continuous Flow. Continuous Care Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy 1-5 L/min of quiet1, pure2, continuous flow oxygen 8-layer internal gas pathway for delivering medical-grade oxygen Co
Slide 15: Latest POC Innovation: Rove 4
Latest POC Innovation: Rove 4 Delivers power and performance in the lightest weight and highest oxygen output 4-setting POC 1 New, 4-setting pulse dose Redesigned symbol-based oxygen concentrator – up to User Interface to facilitate 840 mL/min ease of use Lightweight, only 2.9lbs (1.3 kg) 2 Redesign
Slide 16: Airway Clearance Device: SIMEOX 200 (U.S. Market Only)
Airway Clearance Device: SIMEOX 200 (U.S. Market Only) A unique and novel approach to bronchial mucus clearance for helping chronic lung disease patients efficiently, easily, comfortably clear their lungs 1,2,3 Legacy Simeox SIMEOX 200 (U.S. Only) (International Only) • Patented pneumatic signal tha
Slide 17: Expanding Geographic Reach with SIMEOX 200 Launch in the U.S.
Expanding Geographic Reach with SIMEOX 200 Launch in the U.S. SIMEOX 200 is an airway clearance and mucus management device predominantly aimed at treating bronchiectasis. SIMEOX 200 has received FDA clearance and is an enhanced version of the international version of Simeox, currently being sold in
Slide 18: COPD, Bronchiectasis and Overlap in U.S. Population
COPD, Bronchiectasis and Overlap in U.S. Population COPD affects ~14-15 million people in the United States 1,2 Stage 2-4 COPD Prevalent among adults aged ≥75 years, those living in rural areas, and 14-15M patients smokers Prevalence data underestimates total COPD burden as the disease is usua
Slide 19: Fiscal Year 2024 Financial Profile
Fiscal Year 2024 Financial Profile Revenue Breakdown 2 (12 Months ended December 31, 2024) Annual Revenue $335.7M Gross Margin 46.1% International B2B Domestic B2B 35% 25% Cash, cash equivalents & $117.4M restricted cash 1 Direct-To- Debt 1 $0.0M Consumer sales Rentals 23% 17% 1. As of December 31,
Slide 20: Established Traction Around the World
Established Traction Around the World 20+ Years Broad Geographic Reach Locations in Indicated for Patients with of Leadership in 60+ countries California, Texas, COPD and Bronchiectasis Massachusetts, Netherlands, Evolving to Dyspnea, CHF, Respiratory Therapy Czech Republic 1 Hypercapnia Large, Back
Slide 21: Why Inogen?
Why Inogen? Global market leader with high quality, innovative respiratory therapy Well positioned for growth in core COPD markets globally; expanding indications and patient populations served Sufficient capital to fund sustainable, organic growth Opportunity to improve operating efficiency in the
Slide 22: Improving lives through respiratory care
Improving lives through respiratory care